Комбинацията е противопоказана поради повишен риск от миопатия, включително рабдомиолиза.
Indinavir inhibits CYP3A4 and as a result is expected to markedly increase the plasma concentrations of these HMG-CoA reductase inhibitors, which are highly dependent on CYP3A4 metabolism.